{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:13Z","timestamp":1791828853959,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.semarthrit.2020.03.013","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:03:04Z","timestamp":1589151784000},"page":"544-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Frank","family":"Verhoeven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Weil-Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Di","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Thevenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.03.013_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0002","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0004","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00125-005-1689-3","article-title":"Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study","volume":"48","author":"Tillin","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170361","article-title":"Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis","volume":"12","author":"Hallajzadeh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5152\/eurjrheum.2017.16052","article-title":"Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis","volume":"4","author":"\u00d6zkan","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0008","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0168-8278(02)00413-0","article-title":"A comparison of fibrosis progression in chronic liver diseases","volume":"38","author":"Poynard","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2014.10.023","article-title":"NAFLD incidence and remission: only a matter of weight gain and weight loss?","volume":"62","author":"Marchesini","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0011","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11892-006-0031-x","article-title":"Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver","volume":"6","author":"Boden","year":"2006","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0013","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1194\/jlr.M050237","article-title":"Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells","volume":"55","author":"Leamy","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0014","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0015","doi-asserted-by":"crossref","first-page":"pii: E2082","DOI":"10.3390\/ijms17122082","article-title":"Pathophysiology of non alcoholic fatty liver disease","volume":"1","author":"Petta","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0016","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10238-015-0347-4","article-title":"Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients","volume":"16","author":"Paredes-Turrubiarte","year":"2016","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0043-118666","article-title":"Pivotal role of TNF-\u03b1 in the development and progression of nonalcoholic fatty liver disease in a murine model","volume":"50","author":"Kakino","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0018","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.03.013_bib0020","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00535-012-0678-9","article-title":"The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis","volume":"48","author":"Campanati","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0022","first-page":"1369","article-title":"W. Adalimumab could supress the activity of non-alcoholic steatohepatitis (NASH. Z","volume":"46","author":"Schramm","year":"2008","journal-title":"Gastroenterol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0023","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0024","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0026","article-title":"A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy","author":"J-Paul","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.12021","article-title":"Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications","volume":"33","author":"Bellot","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0028","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0029","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jhep.2006.11.018","article-title":"Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites","volume":"46","author":"Franc\u00e9s","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0030","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0031","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0032","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0033","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2008.10.024","article-title":"Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial","volume":"50","author":"Sharma","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0034","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2133.2005.06681.x","article-title":"Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis","volume":"153","author":"Lehnen","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0035","first-page":"351","article-title":"Etanercept therapy of psoriatic arthritis in a patient with liver cirrhosis","volume":"85","author":"Lehnen","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbspin.2007.03.003","article-title":"Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis","volume":"75","author":"Spadaro","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jbspin.2008.05.004","article-title":"Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis","volume":"76","author":"Ogata","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0038","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jaad.2008.06.019","article-title":"Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver","volume":"59","author":"Piel","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0039","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ecco-jcc\/jjv045","article-title":"Administration of two anti-TNF\u03b1 agents in an ulcerative colitis patient with HBV-related cirrhosis","volume":"9","author":"Desideri","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jbspin.2011.04.014","article-title":"Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis","volume":"78","author":"Kubo","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0041","first-page":"114","article-title":"Successful etanercept treatment for primary biliary cirrhosis associated with rheumatoid arthritis","volume":"17","author":"Kov\u00e1cs","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0042","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00296-015-3366-2","article-title":"Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis","volume":"35","author":"Dimopoulou","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0043","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17843286.2017.1290567","article-title":"Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea","volume":"72","author":"Resorlu","year":"2017","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.03.013_bib0044","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0378-6323.186498","article-title":"Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review","volume":"83","author":"Ergun","year":"2017","journal-title":". Indian J Dermatol Venereol Leprol."},{"issue":"1","key":"10.1016\/j.semarthrit.2020.03.013_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000439587","article-title":"Are anti-TNF-\u03b1 agents safe for treating psoriasis in Hepatitis C virus patients with advanced liver disease? Case reports and review of the literature","volume":"232","author":"Di Nuzzo","year":"2016","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.03.013_bib0046","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.crohns.2008.05.008","article-title":"Infliximab use in a patient with ulcerative colitis and alcoholic cirrhosis with portal hypertension","volume":"Sep;2","author":"Carri\u00f3n","year":"2008","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.03.013_bib0047","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1002\/ibd.21434","article-title":"Use of biologics in inflammatory bowel disease patients with Cirrhosis","volume":"17","author":"Dhere","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0048","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/1346-8138.13981","article-title":"Severe subcutaneous hematoma in a patient with psoriatic arthritis: changes of platelet count in psoriatic patients with biologic agents","volume":"44","author":"Maya","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.03.013_bib0049","first-page":"512","article-title":"Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases","volume":"179","author":"Begon","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.03.013_bib0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:01:08Z","timestamp":1758733268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220300871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0049017220300871"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}